CMPS | tickerfilter.com

Fundamental analysis

38%

Profitability 35%

Dept financing 28%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-6.81%

1 Month

-28.81%

3 Months

-7.69%

6 Months

20.00%

1 Year

92.16%

2 Year

-38.30%

Key data

Stock price

$5.88

P/E Ratio

0.00

DAY RANGE

$5.87 - $6.12

EPS

$556.76

52 WEEK RANGE

$2.25 - $8.90

52 WEEK CHANGE

$98.31

MARKET CAP

549.743 M

YIELD

N/A

SHARES OUTSTANDING

96.017 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-07-2025

BETA

1.60

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,583,616

AVERAGE 30 VOLUME

$5,257,036

Company detail

CEO: Kabir K. Nath
Region: US
Website: compasspathways.com
Employees: 120
IPO year: 2020

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression. The company was formerly known as COMPASS Rx Limited.

CMPS - Compass Pathways Plc